Such ongoing clinical studies and preclinical evidence demonstrate the immunosuppressive effects of BTK inhibitors in autoimmune diseases and warrant further considerations of new clinical trials on BTK inhibitors as therapeutic agents for these autoimmune diseases. Here, BTK is linked to autoimmune disease.